PACAP38 in human models of primary headaches

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

PACAP38 in human models of primary headaches. / Ashina, Håkan; Guo, Song; Vollesen, Anne L H; Ashina, Messoud.

I: Journal of Headache and Pain, Bind 18, 110, 2017.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Ashina, H, Guo, S, Vollesen, ALH & Ashina, M 2017, 'PACAP38 in human models of primary headaches', Journal of Headache and Pain, bind 18, 110. https://doi.org/10.1186/s10194-017-0821-3

APA

Ashina, H., Guo, S., Vollesen, A. L. H., & Ashina, M. (2017). PACAP38 in human models of primary headaches. Journal of Headache and Pain, 18, [110]. https://doi.org/10.1186/s10194-017-0821-3

Vancouver

Ashina H, Guo S, Vollesen ALH, Ashina M. PACAP38 in human models of primary headaches. Journal of Headache and Pain. 2017;18. 110. https://doi.org/10.1186/s10194-017-0821-3

Author

Ashina, Håkan ; Guo, Song ; Vollesen, Anne L H ; Ashina, Messoud. / PACAP38 in human models of primary headaches. I: Journal of Headache and Pain. 2017 ; Bind 18.

Bibtex

@article{e658b01749c84afa8dae0d62e410651e,
title = "PACAP38 in human models of primary headaches",
abstract = "BACKGROUND: To review the role of PACAP38 in human models of primary headaches, discuss possible mechanisms of PACAP38-induced migraine, and outline future directions.DISCUSSION: Experimental studies have established PACAP38 as a potent pharmacological {"}trigger{"} molecule of migraine-like attacks. These studies have also revealed a heterogeneous PACAP38 migraine response in migraine without aura patients. In addition, findings from brain imaging studies have demonstrated neuronal and vascular changes in migraine patients both ictally and interictally after PACAP38 infusion.CONCLUSION: Human migraine models have shed light on the importance of PACAP38 in the pathophysiology of primary headaches. These studies have also pointed to the PAC1receptor and the PACAP38 molecule itself as target sites for drug testing. Future research should seek to understand the mechanisms underlying PACAP38-induced migraine. The results from an ongoing proof of concept randomized clinical trial may reveal the therapeutic potential of anti-PAC1receptor antibodies for migraine prevention.",
author = "H{\aa}kan Ashina and Song Guo and Vollesen, {Anne L H} and Messoud Ashina",
year = "2017",
doi = "10.1186/s10194-017-0821-3",
language = "English",
volume = "18",
journal = "Journal of Headache and Pain",
issn = "1129-2369",
publisher = "Springer",

}

RIS

TY - JOUR

T1 - PACAP38 in human models of primary headaches

AU - Ashina, Håkan

AU - Guo, Song

AU - Vollesen, Anne L H

AU - Ashina, Messoud

PY - 2017

Y1 - 2017

N2 - BACKGROUND: To review the role of PACAP38 in human models of primary headaches, discuss possible mechanisms of PACAP38-induced migraine, and outline future directions.DISCUSSION: Experimental studies have established PACAP38 as a potent pharmacological "trigger" molecule of migraine-like attacks. These studies have also revealed a heterogeneous PACAP38 migraine response in migraine without aura patients. In addition, findings from brain imaging studies have demonstrated neuronal and vascular changes in migraine patients both ictally and interictally after PACAP38 infusion.CONCLUSION: Human migraine models have shed light on the importance of PACAP38 in the pathophysiology of primary headaches. These studies have also pointed to the PAC1receptor and the PACAP38 molecule itself as target sites for drug testing. Future research should seek to understand the mechanisms underlying PACAP38-induced migraine. The results from an ongoing proof of concept randomized clinical trial may reveal the therapeutic potential of anti-PAC1receptor antibodies for migraine prevention.

AB - BACKGROUND: To review the role of PACAP38 in human models of primary headaches, discuss possible mechanisms of PACAP38-induced migraine, and outline future directions.DISCUSSION: Experimental studies have established PACAP38 as a potent pharmacological "trigger" molecule of migraine-like attacks. These studies have also revealed a heterogeneous PACAP38 migraine response in migraine without aura patients. In addition, findings from brain imaging studies have demonstrated neuronal and vascular changes in migraine patients both ictally and interictally after PACAP38 infusion.CONCLUSION: Human migraine models have shed light on the importance of PACAP38 in the pathophysiology of primary headaches. These studies have also pointed to the PAC1receptor and the PACAP38 molecule itself as target sites for drug testing. Future research should seek to understand the mechanisms underlying PACAP38-induced migraine. The results from an ongoing proof of concept randomized clinical trial may reveal the therapeutic potential of anti-PAC1receptor antibodies for migraine prevention.

U2 - 10.1186/s10194-017-0821-3

DO - 10.1186/s10194-017-0821-3

M3 - Review

C2 - 29453754

VL - 18

JO - Journal of Headache and Pain

JF - Journal of Headache and Pain

SN - 1129-2369

M1 - 110

ER -

ID: 194645502